Since the publication of the first edition of this book in 2003, the field of clinical mycology has
derged. This is in no small measure due to increasing numbers of immunosuppressed hosts.
Transplants of both solid organs and stem cells have become commonplace. In addition to
patients who classically have been considered to be immune compromised, the expanded use
of immune modifiers, such as tumor necrosis factor antagonists and other monoclonal antibod-
ies, has created new populations at risk for fungal infections. Advances in intensive care have
allowed survival of desperately ill patients, but also have created another population group at
high risk for invasive fungal infections. Our understanding of the epidemiology of fungal
infections has expanded with detailed studies on risk factors and effects of various prophylac-
tic regimens in specific at-risk populations and with the use of newer molecular methods.

The treatment of fungal infections has improved markedly in the few short years since the
first edition was published. New antifungal agents have been licensed for use, and indications
for the use of various antifungal agents have changed. New agents in the echinocandin and
azole classes of drugs and the increasing use of lipid formulations of amphotericin B have
allowed safer and more effective therapy for severe fungal infections, especially in immuno-
suppressed patients. The scientific basis of antifungal therapy has been enhanced with new
studies on the pharmacodynamics and pharmacokinetics of these agents. Unfortunately, and
perhaps not unexpectedly, these positive developments have been tempered by increasing
resistance to several classes of antifungal agents.

For each of the medically important fungal diseases, we have attempted to integrate basic
aspects of mycology pertinent to an understanding of pathogenesis of infection with an exten-
sive discussion of clinical manifestations, diagnosis, and treatment. Color photographs are
used extensively to illustrate the many different manifestations of fungal infections.

The book is organized, as before, into several distinct sections and is extensively indexed to
allow easy access to the topics pertinent to patients cared for by busy clinicians. Part I gives a
general overview of laboratory aspects of mycology, emphasizing newer molecular techniques
that are assuming increasing importance in diagnosis, and of epidemiologic trends in fungal
infections. The chapters in Part II give an in-depth review of the antifungal agents available for
the treatment of systemic fungal infections. In addition, specific chapters deal with the expand-
ingen area of pharmacokinetics and pharmacodynamics, the increasing problem of antifungal
resistance, and the use of combination antifungal therapy. Parts III–VI are devoted to individ-
ual fungal diseases, and are arranged by diseases caused by yeasts (Part III), moulds (Part IV),
dimorphic or endemic fungi (Part V), and other mycoses (Part VI). The final section (Part VII)
is devoted to specific immunosuppressed populations who are at high risk for fungal
infections.

It is hoped that this text will provide a valuable resource for clinicians who do battle with
the medically important fungi in their daily practices, as well as for those who only infre-
duently are faced with the “odd case” that could possibly be an unusual fungal infection.

C.A.K., P.G.P., J.D.S., W.E.D.
Essentials of Clinical Mycology
Kauffman, C.A.; Pappas, P.G.; Sobel, J.D.; Dismukes, W.E. (Eds.)
2011, XIII, 553 p., Hardcover
ISBN: 978-1-4419-6639-1